Processa Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value
Processa Pharmaceuticals, Inc. (PCSA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value of $1.88 per share for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-20.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue · last filed 2017-11-20
- Processa Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for the quarter ending 2017-03-31 was $1.64, a 7.19% increase year-over-year.
- Processa Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for the quarter ending 2016-03-31 was $1.53, a 49.00% decline year-over-year.
- Processa Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for the quarter ending 2015-03-31 was $3.00, a 50.00% increase year-over-year.
- Processa Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for the quarter ending 2014-03-31 was $2.00.
- Processa Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for fiscal 2016 was $1.69, a 27.47% decline from fiscal 2015.
- Processa Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for fiscal 2015 was $2.33, a 5.28% decline from fiscal 2014.
- Processa Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for fiscal 2014 was $2.46, a 23.00% increase from fiscal 2013.
- Processa Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for fiscal 2013 was $2.00.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2017-09-30 | $1.88 10-Q · filed 2017-11-20 | |||
| 2017-06-30 | $1.75 10-Q · filed 2017-10-04 | |||
| 2017-03-31 | $1.64 10-Q · filed 2017-10-04 | |||
| 2016-12-31 | $1.69 10-K · filed 2017-09-25 | |||
| 2016-09-30 | $1.69 10-Q · filed 2017-09-08 | |||
| 2016-06-30 | $1.53 10-Q · filed 2017-08-30 | |||
| 2016-03-31 | $1.53 10-Q · filed 2017-08-07 | |||
| 2015-12-31 | $2.33 10-K · filed 2017-09-25 | |||
| 2015-09-30 | $2.36 10-Q · filed 2015-12-01 | |||
| 2015-06-30 | $2.35 10-Q · filed 2015-08-19 | |||
| 2015-03-31 | $3.00 10-Q · filed 2015-05-15 | |||
| 2014-12-31 | $2.46 10-K · filed 2017-06-19 | |||
| 2014-09-30 | $2.25 10-Q · filed 2014-11-13 | |||
| 2014-06-30 | $2.27 10-Q · filed 2014-08-19 | |||
| 2014-03-31 | $2.00 10-Q · filed 2014-05-14 | |||
| 2013-12-31 | $2.00 10-K · filed 2015-04-14 | |||
| 2013-09-30 | $2.00 10-Q · filed 2013-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |